AU2013268364B2 - Therapeutic agent or prophylactic agent for dementia - Google Patents
Therapeutic agent or prophylactic agent for dementia Download PDFInfo
- Publication number
- AU2013268364B2 AU2013268364B2 AU2013268364A AU2013268364A AU2013268364B2 AU 2013268364 B2 AU2013268364 B2 AU 2013268364B2 AU 2013268364 A AU2013268364 A AU 2013268364A AU 2013268364 A AU2013268364 A AU 2013268364A AU 2013268364 B2 AU2013268364 B2 AU 2013268364B2
- Authority
- AU
- Australia
- Prior art keywords
- ser
- gly
- lys
- pro
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018200413A AU2018200413B2 (en) | 2012-05-31 | 2018-01-18 | Therapeutic agent or prophylactic agent for dementia |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012124336 | 2012-05-31 | ||
| JP2012-124336 | 2012-05-31 | ||
| PCT/JP2013/065090 WO2013180238A1 (ja) | 2012-05-31 | 2013-05-30 | 認知症治療剤又は予防剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018200413A Division AU2018200413B2 (en) | 2012-05-31 | 2018-01-18 | Therapeutic agent or prophylactic agent for dementia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013268364A1 AU2013268364A1 (en) | 2014-12-18 |
| AU2013268364B2 true AU2013268364B2 (en) | 2018-02-08 |
Family
ID=49673425
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013268364A Active AU2013268364B2 (en) | 2012-05-31 | 2013-05-30 | Therapeutic agent or prophylactic agent for dementia |
| AU2018200413A Active AU2018200413B2 (en) | 2012-05-31 | 2018-01-18 | Therapeutic agent or prophylactic agent for dementia |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018200413A Active AU2018200413B2 (en) | 2012-05-31 | 2018-01-18 | Therapeutic agent or prophylactic agent for dementia |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20150183854A1 (enExample) |
| EP (2) | EP2857039B1 (enExample) |
| JP (3) | JP5971659B2 (enExample) |
| KR (2) | KR102208283B1 (enExample) |
| CN (1) | CN104602708B (enExample) |
| AR (1) | AR091218A1 (enExample) |
| AU (2) | AU2013268364B2 (enExample) |
| BR (1) | BR112014029566A2 (enExample) |
| CA (1) | CA2875205C (enExample) |
| CY (1) | CY1122530T1 (enExample) |
| DK (1) | DK2857039T3 (enExample) |
| ES (2) | ES2973070T3 (enExample) |
| HR (1) | HRP20192267T1 (enExample) |
| HU (1) | HUE046919T2 (enExample) |
| IL (1) | IL235899B (enExample) |
| LT (1) | LT2857039T (enExample) |
| ME (1) | ME03587B (enExample) |
| MX (1) | MX361128B (enExample) |
| MY (1) | MY172458A (enExample) |
| NZ (1) | NZ630536A (enExample) |
| PH (1) | PH12014502669B1 (enExample) |
| PL (1) | PL2857039T3 (enExample) |
| PT (1) | PT2857039T (enExample) |
| RS (1) | RS59802B1 (enExample) |
| RU (1) | RU2657438C2 (enExample) |
| SG (2) | SG11201407878VA (enExample) |
| SI (1) | SI2857039T1 (enExample) |
| TW (2) | TWI777183B (enExample) |
| WO (1) | WO2013180238A1 (enExample) |
| ZA (1) | ZA201409186B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2826286C (en) | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| EP2709728B1 (en) * | 2011-05-20 | 2019-01-23 | Oligomerix, Inc. | Tau protease methods of use |
| MY172458A (en) * | 2012-05-31 | 2019-11-26 | Teijin Pharma Ltd | Therapeutic agent or prophylactic agent for dementia |
| MY171473A (en) | 2012-07-03 | 2019-10-15 | Univ Washington | Antibodies to tau |
| TW202136296A (zh) | 2014-06-27 | 2021-10-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| US20190224339A1 (en) * | 2016-04-29 | 2019-07-25 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| JP6785372B2 (ja) * | 2016-09-30 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ |
| MA47499A (fr) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc | Anticorps anti-tau et leurs procédés d'utilisation |
| JOP20180014A1 (ar) * | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
| CN110691794B (zh) | 2017-05-30 | 2023-10-27 | 帝人制药株式会社 | 抗igf-i受体抗体 |
| GEP20227406B (en) | 2017-10-02 | 2022-08-25 | Merck Sharp & Dohme | Chromane monobactam compounds for the treatment of bacterial infections |
| WO2019077500A1 (en) | 2017-10-16 | 2019-04-25 | Eisai R&D Management Co., Ltd. | ANTI-WATER ANTIBODIES AND USES THEREOF |
| JP7504026B2 (ja) | 2018-04-06 | 2024-06-21 | 帝人ファーマ株式会社 | Ｓｐｎｓ２中和抗体 |
| JP7340794B2 (ja) * | 2018-07-04 | 2023-09-08 | 学校法人 愛知医科大学 | タウのスプライシングを制御するアンチセンスオリゴヌクレオチド及びその用途 |
| CN110028583B (zh) * | 2019-05-07 | 2020-09-11 | 温州医科大学 | 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用 |
| JP7429404B2 (ja) * | 2019-08-06 | 2024-02-08 | 慶應義塾 | タウ関連疾患モデルの製造方法 |
| JP7718270B2 (ja) | 2019-09-30 | 2025-08-05 | ニプロ株式会社 | 血液試料を検体とするタウタンパク質検出方法 |
| EP4121071A4 (en) * | 2020-03-19 | 2024-07-24 | Vascular Biosciences | PEPTIDE CAR FOR IMPROVED CORONAVIRUS SURVIVAL |
| BR112022026575A2 (pt) | 2020-06-25 | 2023-01-17 | Merck Sharp & Dohme Llc | Anticorpos de alta afinidade que alvejam tau fosforilado em serina 413 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| AU2023342086A1 (en) | 2022-09-15 | 2025-03-13 | Voyager Therapeutics, Inc. | Tau binding compounds |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010144711A2 (en) * | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS587390B2 (ja) | 1975-03-11 | 1983-02-09 | ツキシマキカイ カブシキガイシヤ | ア−クヨウセツホウホウ |
| JP3587390B2 (ja) | 1994-03-17 | 2004-11-10 | タカラバイオ株式会社 | リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法 |
| US20020086009A1 (en) * | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
| US20080199471A1 (en) * | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20070280935A1 (en) * | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| EP2028932A4 (en) * | 2006-06-16 | 2011-10-12 | Vitruvean Llc | TAU AND AMYLOID FOREIGNER FRAGMENT EXPRESSING TRANSGENIC FLY |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| CA2826286C (en) * | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| TR201102696U (tr) * | 2011-05-27 | 2011-06-21 | Turhal Sal�H | Bağlantısız hareketli ürün reklam standı. |
| MY172458A (en) * | 2012-05-31 | 2019-11-26 | Teijin Pharma Ltd | Therapeutic agent or prophylactic agent for dementia |
| JOP20180014A1 (ar) * | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
-
2013
- 2013-05-30 MY MYPI2014703534A patent/MY172458A/en unknown
- 2013-05-30 RS RS20191640A patent/RS59802B1/sr unknown
- 2013-05-30 SI SI201331636T patent/SI2857039T1/sl unknown
- 2013-05-30 JP JP2014518734A patent/JP5971659B2/ja active Active
- 2013-05-30 EP EP13797290.7A patent/EP2857039B1/en active Active
- 2013-05-30 HU HUE13797290A patent/HUE046919T2/hu unknown
- 2013-05-30 ES ES19207405T patent/ES2973070T3/es active Active
- 2013-05-30 KR KR1020207007010A patent/KR102208283B1/ko active Active
- 2013-05-30 CA CA2875205A patent/CA2875205C/en active Active
- 2013-05-30 TW TW109121902A patent/TWI777183B/zh active
- 2013-05-30 US US14/403,803 patent/US20150183854A1/en not_active Abandoned
- 2013-05-30 WO PCT/JP2013/065090 patent/WO2013180238A1/ja not_active Ceased
- 2013-05-30 NZ NZ630536A patent/NZ630536A/en unknown
- 2013-05-30 SG SG11201407878VA patent/SG11201407878VA/en unknown
- 2013-05-30 CN CN201380040658.9A patent/CN104602708B/zh active Active
- 2013-05-30 ME MEP-2019-341A patent/ME03587B/me unknown
- 2013-05-30 BR BR112014029566A patent/BR112014029566A2/pt not_active Application Discontinuation
- 2013-05-30 AU AU2013268364A patent/AU2013268364B2/en active Active
- 2013-05-30 SG SG10201805410XA patent/SG10201805410XA/en unknown
- 2013-05-30 HR HRP20192267TT patent/HRP20192267T1/hr unknown
- 2013-05-30 AR ARP130101907 patent/AR091218A1/es active IP Right Grant
- 2013-05-30 MX MX2014014187A patent/MX361128B/es active IP Right Grant
- 2013-05-30 EP EP19207405.2A patent/EP3662931B1/en active Active
- 2013-05-30 LT LTEP13797290.7T patent/LT2857039T/lt unknown
- 2013-05-30 ES ES13797290T patent/ES2763361T3/es active Active
- 2013-05-30 DK DK13797290.7T patent/DK2857039T3/da active
- 2013-05-30 TW TW102119176A patent/TWI700296B/zh active
- 2013-05-30 RU RU2014153099A patent/RU2657438C2/ru active
- 2013-05-30 PL PL13797290T patent/PL2857039T3/pl unknown
- 2013-05-30 PT PT137972907T patent/PT2857039T/pt unknown
- 2013-05-30 KR KR1020147035417A patent/KR102133610B1/ko active Active
-
2014
- 2014-11-25 IL IL235899A patent/IL235899B/en active IP Right Grant
- 2014-11-28 PH PH12014502669A patent/PH12014502669B1/en unknown
- 2014-12-12 ZA ZA2014/09186A patent/ZA201409186B/en unknown
-
2016
- 2016-05-09 JP JP2016094112A patent/JP6406678B2/ja active Active
-
2018
- 2018-01-18 AU AU2018200413A patent/AU2018200413B2/en active Active
- 2018-03-19 JP JP2018051046A patent/JP6620829B2/ja active Active
-
2019
- 2019-06-10 US US16/436,301 patent/US20200148753A1/en not_active Abandoned
- 2019-12-13 CY CY20191101311T patent/CY1122530T1/el unknown
-
2021
- 2021-12-01 US US17/539,926 patent/US20220340646A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010144711A2 (en) * | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220340646A1 (en) | Therapeutic agent or prophylactic agent for dementia | |
| JP7012004B2 (ja) | シヌクレイノパチーの治療のための薬剤、使用および方法 | |
| JP2018139530A (ja) | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 | |
| EP4488292A1 (en) | Therapeutic agent for neurodegenerative disorder | |
| TW201702273A (zh) | 用於治療的藥劑、用途及方法 | |
| HK40031828A (en) | Therapeutic agent or prophylactic agent for dementia | |
| HK40031828B (en) | Therapeutic agent or prophylactic agent for dementia | |
| WO2025047850A1 (ja) | 神経変性疾患の治療剤 | |
| HK1210031B (zh) | 痴呆症治疗药或预防药 | |
| HK40120105A (en) | Therapeutic agent for neurodegenerative disorder | |
| CN118804929A (zh) | 神经变性疾病的治疗剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: OSAKA CITY UNIVERSITY Free format text: FORMER OWNER(S): TEIJIN PHARMA LIMITED; OSAKA CITY UNIVERSITY Owner name: TEIJIN LIMITED Free format text: FORMER OWNER(S): TEIJIN PHARMA LIMITED; OSAKA CITY UNIVERSITY |